Julie S. Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julie S. Kim has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Afsane Radmand
School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, USA
1 shared publication - Alexandra N. Newby
Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, USA
1 shared publication - Angela Malaney
Department of Chemical Engineering Carnegie Mellon University Pittsburgh Pennsylvania USA
1 shared publication - B. Pradeep Kumar Reddy
School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, USA
1 shared publication Bethany Fox
Mellon Institute Centralized Vivarium, Carnegie Mellon University, Pittsburgh, PA 15213
1 shared publication- Catalina Montoya
Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213
1 shared publication
Latest Publications
- Open Access
- 2 September 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (7) , 2256-2271
Development of a microneedle patch for delivery of mRNA-lipid nanoparticles
MRNA delivered by microneedle patch (MNP) can enable painless delivery, reduced need for healthcare expertise, and improved thermostability. In this study, we investigated formulation and manufacturing approaches for developing MNPs that deliver mRNA-loaded lipid nanoparticles (LNPs) encoding luciferase as a reporter protein during MNP fabrication and storage, including mRNA-LNP concentration, formulation, pH, excipients, and backing material. MNPs were assessed for mRNA-LNP size, encapsulation efficiency, and protein expression in vitro and in vivo. MNPs fabricated with mRNA-LNPs initially prepared at a higher concentration yielded superior expression compared to mRNA-LNP concentration by centrifugation or tangential flow filtration. Acidic pH during MNP manufacturing enabled greater expression in vitro. However, no such correlation was observed in vivo. Polyvinyl alcohol (PVA) best stabilized mRNA-LNPs during the MNP manufacturing process amongst the tested polymers. Incorporating sugars in MNPs did not further improve stability. Low temperature drying (5 °C) preserved mRNA functionality better compared to drying at 25 °C and 40 °C. Though there was significant activity loss initially (87% loss in 2 days at 40 °C), mRNA expression was stabilized for extended subsequent periods even at accelerated conditions (10% additional loss after 28 days at 40 °C). Our systematic approach identified key parameters for successful formulation and manufacturing approaches to incorporate mRNA-LNPs into MNPs, which could expand access to mRNA-based medical interventions.
- 2 September 2025
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (7) , 2256-2271
Open AccessDevelopment of a microneedle patch for delivery of mRNA-lipid nanoparticles
MRNA delivered by microneedle patch (MNP) can enable painless delivery, reduced need for healthcare expertise, and improved thermostability. In this study, we investigated formulation and manufacturing approaches for developing MNPs that deliver mRNA-loaded lipid nanoparticles (LNPs) encoding luciferase as a reporter protein during MNP fabrication and storage, including mRNA-LNP concentration, formulation, pH, excipients, and backing material. MNPs were assessed for mRNA-LNP size, encapsulation efficiency, and protein expression in vitro and in vivo. MNPs fabricated with mRNA-LNPs initially prepared at a higher concentration yielded superior expression compared to mRNA-LNP concentration by centrifugation or tangential flow filtration. Acidic pH during MNP manufacturing enabled greater expression in vitro. However, no such correlation was observed in vivo. Polyvinyl alcohol (PVA) best stabilized mRNA-LNPs during the MNP manufacturing process amongst the tested polymers. Incorporating sugars in MNPs did not further improve stability. Low temperature drying (5 °C) preserved mRNA functionality better compared to drying at 25 °C and 40 °C. Though there was significant activity loss initially (87% loss in 2 days at 40 °C), mRNA expression was stabilized for extended subsequent periods even at accelerated conditions (10% additional loss after 28 days at 40 °C). Our systematic approach identified key parameters for successful formulation and manufacturing approaches to incorporate mRNA-LNPs into MNPs, which could expand access to mRNA-based medical interventions.
- Open Access
- 4 March 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (11)
Lipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes
Treating pregnancy-related disorders is exceptionally challenging because the threat of maternal and/or fetal toxicity discourages the use of existing medications and hinders new drug development. One potential solution is the use of lipid nanoparticle (LNP) RNA therapies, given their proven efficacy, tolerability, and lack of fetal accumulation. Here, we describe LNPs for efficacious mRNA delivery to maternal organs in pregnant mice via several routes of administration. In the placenta, our lead LNP transfected trophoblasts, endothelial cells, and immune cells, with efficacy being structurally dependent on the ionizable lipid polyamine headgroup. Next, we show that LNP-induced maternal inflammatory responses affect mRNA expression in the maternal compartment and hinder neonatal development. Specifically, pro-inflammatory LNP structures and routes of administration curtailed efficacy in maternal lymphoid organs in an IL-1β-dependent manner. Further, immunogenic LNPs provoked the infiltration of adaptive immune cells into the placenta and restricted pup growth after birth. Together, our results provide mechanism-based structural guidance on the design of potent LNPs for safe use during pregnancy.
- 4 March 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (11)
Open AccessLipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes
Treating pregnancy-related disorders is exceptionally challenging because the threat of maternal and/or fetal toxicity discourages the use of existing medications and hinders new drug development. One potential solution is the use of lipid nanoparticle (LNP) RNA therapies, given their proven efficacy, tolerability, and lack of fetal accumulation. Here, we describe LNPs for efficacious mRNA delivery to maternal organs in pregnant mice via several routes of administration. In the placenta, our lead LNP transfected trophoblasts, endothelial cells, and immune cells, with efficacy being structurally dependent on the ionizable lipid polyamine headgroup. Next, we show that LNP-induced maternal inflammatory responses affect mRNA expression in the maternal compartment and hinder neonatal development. Specifically, pro-inflammatory LNP structures and routes of administration curtailed efficacy in maternal lymphoid organs in an IL-1β-dependent manner. Further, immunogenic LNPs provoked the infiltration of adaptive immune cells into the placenta and restricted pup growth after birth. Together, our results provide mechanism-based structural guidance on the design of potent LNPs for safe use during pregnancy.
- 31 December 2022
- Published by Rutgers University Press
- p. 52-70
2 Money Matters in Immigrant Motherhood
2 Money Matters in Immigrant Motherhood was published in Redefining Multicultural Families in South Korea on page 52.
- 31 December 2022
- Published by Rutgers University Press
- p. 52-70
2 Money Matters in Immigrant Motherhood
2 Money Matters in Immigrant Motherhood was published in Redefining Multicultural Families in South Korea on page 52.